Crafting a genomics strategy early is key for successful oncology drug development

Discover three key considerations for crafting a successful genomic biomarker strategy in this article.

An historic shift towards treating cancer based on a tumor’s genetics rather than its site of origin is underway. Genomically-targeted drugs, properly developed, have an inherent advantage over drugs that are not. But the success of any one will depend on good strategic planning, done early. Read about three key considerations for crafting a successful genomic biomarker strategy.

Crafting a genomics strategy early is key for successful oncology drug development

Importance of Diversity, Equity and Inclusion (DE&I) in medical communications

Battling rare disease: personally and professionally

The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

We need faster endpoints for targeted cancer drugs, and there is one

The impact of COVID-19 on clinical trials in rare disease and oncology

Five competencies for operational excellence in cell and gene therapy clinical trials

Three ways to improve your chances that insurers will pay for a new CGT

How market exclusivities can affect your development program

Parexel on the pulse

Drug Development for Rare Disease and Oncology During the COVID-19 Pandemic

Virtual meetings are easy, right?

Parexel on the Pulse

Five points to remember if FDA issues a Form 483

Hong Kong Exchange: Nurturing China’s Biotech Valley

eBook: Biopharma in the COVID-19 World

NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020

Top 10 Myths About Working with the FDA for an Oncology Drug Approval

GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”

FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with COVID-19

Using risk assessment decision tree models to maintain safety and data validity in clinical trials during COVID-19